Evidence map›Paper›PMID 33469831›Full record

ArticlePituitary2021

Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence.

Salvatore Giovinazzo, Soraya Puglisi, Oana R Cotta, Angela Alibrandi, Tommaso Aversa, Laura Cannavò, Francesco Ferraù, Salvatore Cannavò

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Metabolic effects of prolactin.Frontiers in endocrinology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Salvatore Giovinazzo *Endocrine Unit, University Hospital 'G. Martino', Messina, Italy.
Soraya Puglisi *Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Oana R CottaEndocrine Unit, University Hospital 'G. Martino', Messina, Italy.
Angela AlibrandiDepartment of Economics, Unit of Statistical and Mathematical Sciences, University of Messina, Messina, Italy.
Tommaso AversaDepartment of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.
Laura CannavòDepartment of Human Pathology in Adulthood and Childhood, University of Messina, Messina, Italy.
Francesco FerraùEndocrine Unit, University Hospital 'G. Martino', Messina, Italy. francesco.ferrau1@gmail.com.ORCID http://orcid.org/0000-0002-7472-6598
Salvatore CannavòEndocrine Unit, University Hospital 'G. Martino', Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePituitary adenomas (PAs) rarely occur in childhood and adolescence. Management of PAs in this critical age can be particularly challenging considering the auxological sequelae and potential long-term cardiometabolic consequences. We aimed to describe the clinical characteristics of patients with PA aged < 18years at diagnosis and during long-term follow-up, focusing on the prevalence of cardio-metabolic comorbidities and the impact of different therapeutic strategies.

methodsClinical data at diagnosis and at last follow-up visit (mean 10.3 ± 9.2 years) of 101 patients aged < 18 years with PA, referred to our University Hospital from 1990 to 2017, were retrospectively evaluated.

resultsAt diagnosis, 11.9% of patients presented with pituitary hormone deficiencies, whose number was positively correlated with pituitary tumor diameter (p < 0.001). At diagnosis, 26.7% of patients were overweight and 15.8% were obese. In patients with hypercortisolism or GH excess the prevalence of obesity was more than 2-fold greater than in general population. No correlation was found between pituitary tumor size and BMI. At baseline, the greater the number of pituitary hormone deficits, the higher BMI (p = 0.039). In prolactinoma patients still on medical therapy at last visit, BMI was higher than at baseline.

conclusionWe found an increased prevalence of overweight/obesity only in pediatric and adolescent patients with GH- or ACTH-secreting PA. Regarding cardio-metabolic comorbidities other than obesity/overweight, we have not found anything worth of mention. The remission of hypercortisolism positively impacted on BMI, while medical therapy in patients with prolactinoma seemed unable to avoid weight gain, suggesting a careful metabolic management of these patients.

Indexed as

AdenomaCardiovascular DiseasesPituitary NeoplasmsAdolescentChildCushing SyndromeHumansOverweightRetrospective StudiesBody mass indexCardiometabolicHypopituitarismPediatric pituitary tumorPituitary adenoma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.